CYPHERPUNK TECHNOLOGIES INC. Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value
CYPHERPUNK TECHNOLOGIES INC. (CYPH) had Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value of $3.45 million as of 2018-12-31, per its 10-K filed 2020-03-16.
Discontinued › Notes › Fair Value Measures and Disclosures › Fair Value Disclosures
us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue · last filed 2020-03-16
- 2018-12-31: Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value $3.45M.
- 2017-12-31: Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value $11.86M.
| Period end | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value |
|---|---|
| 2018-12-31 | $3.45M 10-K · filed 2020-03-16 |
| 2017-12-31 | $11.86M 10-K · filed 2020-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |